Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors

Abstract

Significant agreement was detected when the WHO, RECIST 1.1, EORTC, and PERCIST criteria were compared both within as well as between each other.

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point18F-FDG PET/CT Imaging in Patients with Advanced Melanoma

“…Intercriteria agreements between RECIST 1.1, PERCIST, and EORTC were good to excellent at SCAN-3, performed 4 mo after ICI was initiated, which is in accordance with a previous report using cytotoxic chemotherapy (19). However, interestingly, intercriteria agreement between the PET and CT modalities was not good in the early course of ICI therapy.…”

“…Disease response to therapy has been evaluated in multiple studies encompassing a variety of tumor types using these metrics (17)(18)(19).…”

Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments

“…Several recent studies have compared response assessment by EORTC PET criteria and PERCIST [17–22, 24–27]. A meta-analysis of 6 studies including 348 patients concluded that EORTC criteria and PERCIST “showed almost perfect concordance” with a kappa of 0.946 [28].…”

“…So far, however, there only relatively few and mostly small studies comparing RECIST and PERCIST (References: [17] [42] [43] [44] [45] [46] [47] [48] [20] [49] [50] [51] [21] [52] [53] [24] [23] [25] [54] [26] [55] [56]). A meta-analysis published in 2016 identified 6 studies including 268 patients [57].…”

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea

“…This treatment was continued until response evaluation criteria in solid tumors (RECIST)-defined progressive disease and cumulative toxic effects were developed, or if the patients chose to discontinue the treatment. [12] A research nurse or doctor in every center checked the toxicities of the registered medication in this study. Regarding the follow-up schedule, all patients were administered treatment on days 1, 8, and 15 every 4 weeks in subsequent cycles.…”